Skip to content

A multicenter study aiming to create evidence for clinical biomarkers in autoimmune retinopathy

A multicenter study aiming to create evidence for clinical biomarkers in autoimmune retinopathy - Clinical biomarkers in autoimmune retinopathy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000046423
Enrollment
220
Registered
2022-01-01
Start date
2022-09-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

autoimmune retinopathy

Interventions

None listed

Sponsors

Kobe University Graduate School of Medicine
Lead Sponsor
Yamaguchi University Osaka University Yamagata University
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: [Patinet with autoimmune retinopathy] Patinet who meets all of the following: (1) sudden-onset visual disorder (2) no cause of visual disorder is specified in a routine clinical examination (3) abnotmal electroretinogram (4) absence of fundus findings and retnal degeneration/retinal distrophy which can explain visual disorder (5) absence of apparent ocular inflamation (6) presence of outer retinal abnormality on optical coherence tomography (OCT) [Healthy volunteer] Healthy adult who shows no ocular abnormality except for mild cataract

Exclusion criteria

Exclusion criteria: [Patinet with autoimmune retinopathy] (1) uveitis with specific cause (2) inherited retinal diseases (3) optic nerve disorders (4) opacification in anterior segment of the eye and/or optic media which precludes fundus assessment (5) drug-induced retinal disorders (6) aged younger than 20 years (7) patinet who disagrees with this study (8) patinet who the attending doctor judges as ineligibile to participate in this study [Healthy volunteer] Individual who disagrees with this study

Design outcomes

Primary

MeasureTime frame
change in best-corrected visual acuity improvement from baseline to 6 months

Secondary

MeasureTime frame
the following parameters during 6-month follow-up: (1) change in visual field from baseline to 6 months (2) change in optical coherence tomography findings (3) change in comprehenisive protein array data from blood samples (4) change in metabolome profile from blood samples (5) difference in comprehenisive protein array data from blood samples between patinets with autoimmune retinopathy and healthy volunteers (6) difference in metabolome profile from blood samples between patinets with autoimmune retinopathy and healthy volunteers (7) adverse events

Countries

Japan

Contacts

Public ContactSentaro Kusuhara

Kobe University Graduate School of Medicine Division of Ophthalmology, Department of Surgery

kusu@med.kobe-u.ac.jp078-382-6048

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026